Oppenheimer Maintains Outperform on Amrize, Lowers Price Target to $65
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
Oppenheimer analyst Bryan Blair maintains Amrize (NYSE:AMRZ) with a Outperform and lowers the price target from $68 to $65.
Oppenheimer analyst Bryan Blair maintains Amrize (NYSE:AMRZ) with a Outperform and lowers the price target from $68 to $65.